^
Association details:
| Biomarker: | ALK rearrangement + TP53 R175H + EGFR A839V + PI3KCA mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-Small-Cell Lung Cancer
Published date:
08/22/2019
Excerpt:
We asked whether single circulating tumor cell (CTC) sequencing can inform on resistance mutations to ALK inhibitors and underlying tumor heterogeneity in ALK-rearranged NSCLC....We investigated the VAF of resistance mutations in CTCs from 14 ALK-rearranged patients progressing on crizotinib...P4 harbored a TP53R175H mutation (VAF, 100%) in CTC-3 specimen which was also detected in the corresponding tumor biopsy (VAF, 53%). Two additional mutations in PI3KCA and TP53 genes (VAFs, 6%) were detected in CTC-6 specimen of this patient.
DOI:
10.1158/1078-0432.CCR-19-1176
